Consequently, IL-15, in combination with TIM-3 blocking antibodies, could potentially act as an IL-2 alternative in tumor CD8 T cell expansion in vitro, an essential event for adoptive T cell therapy [107]. The gene discussed is HAVCR2; the disease is neoplasm.